Phio Pharmaceuticals Corp
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
PHIO$0.84+4.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| ITEM 6. | EXHIBITS |
|---|
EXHIBIT INDEX
| Incorporated by Reference Herein | |||
| Exhibit Number | Description | Form | Date |
| 31.1 | Sarbanes-Oxley Act Section 302 Certification of Principal Executive Officer and Principal Financial Officer. * | ||
| 32.1 | Sarbanes-Oxley Act Section 906 Certification of Principal Executive Officer and Principal Financial Officer. ** | ||
| 101.INS | Inline XBRL Instance Document.* | ||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document.* | ||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document.* | ||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document.* | ||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document.* | ||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document.* | ||
| 104 | The cover page for this report, formatted in Inline XBRL (included in Exhibit 101).* | ||
| _________________ | |
|---|---|
| * | Filed herewith. |
| ** | Furnished herewith and not deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section or incorporated by reference into any filing under the Securities Act or the Exchange Act. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.